After a platelet transfusion, the raw rise in platelet count depends heavily on the patient's size and how many platelets were transfused — so a bigger patient given a smaller dose can look like a 'poor responder' even with a completely normal transfusion response. The corrected count increment (CCI) standardizes the increment for both factors, making it the standard tool for judging whether a platelet transfusion worked and for screening for platelet refractoriness.

How the CCI formula works

CCI = [(post-transfusion platelet count − pre-transfusion platelet count) × body surface area] / platelets transfused. The platelet counts are entered in ×10³/µL, matching standard lab reporting, and are converted to an absolute cells-per-microliter increment before the formula is applied. Platelets transfused is expressed in ×10¹¹ — a standard single-donor apheresis unit contains roughly 3.0×10¹¹ platelets, while a pooled or random-donor unit contains roughly 0.55×10¹¹.

Dividing by the dose transfused and multiplying by BSA means the same absolute rise in platelet count produces a very different CCI depending on how large the patient is and how many platelets were given — which is exactly the point: it lets clinicians compare the quality of the response, not just the raw number.

Reading the result: adequate, borderline, or poor response

This calculator classifies the CCI against commonly cited cutoffs for each of the two conventional sampling windows. At 1 hour, a CCI of 7,500 or higher is generally considered an adequate response, and below 5,000 is considered a poor response; the range in between is borderline. At 18-24 hours (sometimes reported as 20 hours), the bar is lower — roughly 4,400 or higher is adequate and below 2,500 is poor — because some decline in the increment over a day is expected even in a good responder.

Exact cutoffs vary somewhat between sources (MDCalc, blood-bank reference tables, and the original clinical literature do not all use identical numbers), so treat these as commonly used reference points rather than a single universal law.

From a poor response to a refractoriness diagnosis

A single low CCI does not mean a patient is refractory. Platelet transfusion refractoriness is formally diagnosed only after at least two consecutive inadequate responses to ABO-compatible, fresh (less than 72 hours old) platelet units. The workup starts by ruling out the common non-immune causes of poor platelet survival — fever, sepsis, disseminated intravascular coagulation (DIC), splenomegaly, active bleeding, and graft-versus-host disease — since these are far more frequent than immune causes. If no non-immune cause explains the pattern, platelet antibody testing (HLA and platelet-specific) is used to confirm alloimmunization, which then guides whether HLA-matched or crossmatched platelets are needed for future transfusions.